Deborah Telman,
No reason was given Wednesday in the securities filing for Telman’s pending departure. It comes six months after the drug giant finalized a $202 million settlement with the US government over claims that it paid kickbacks to doctors as an inducement for prescribing the company’s HIV drugs. Gibson, Dunn & Crutcher LLP represented Gilead in that agreement, one of several HIV-related drug cases the biopharmaceutical company has sought to resolve in recent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.